HB 2397-2 (LC 1003) 3/28/23 (SCT/ps)

Requested by Representative DEXTER

PROPOSED AMENDMENTS TO HOUSE BILL 2397

In line 2 of the printed bill, after "prevention" insert "; creating new provisions; and amending ORS 414.318 and 475.525".

3 Delete lines 4 through 8 and insert:

"SECTION 1. (1) As used in this section, 'harm reduction supplies' means opioid reversal medications, hypodermic syringes or needles, single-use drug test strips, drug testing tools or any other item designed to prevent or reduce the potential harm associated with the use of opioids and other controlled substances, including but not limited to items that reduce the risk of transmission of infectious disease or prevent injury, infection or overdose.

11 "(2) The Harm Reduction Clearinghouse Project is established in the 12 Oregon Health Authority to purchase in bulk harm reduction supplies 13 for use throughout this state by community organizations, first 14 responders and other entities that serve populations who are vulner-15 able to overdose, infections or injuries due to opioid use and use of 16 other controlled substances. Entities that may participate in the 17 project include but are not limited to:

- 18 "(a) Hospitals and emergency departments;
- 19 "(b) First responders;
- 20 "(c) Law enforcement agencies;
- ²¹ "(d) Courts and other departments within the criminal justice sys-

1 **tem;**

"(e) Organizations that provide services to individuals experiencing
homelessness;

"(f) Organizations that provide services to individuals at risk of
overdose, infections or injuries related to opioid use or use of other
controlled substances;

7 "(g) Veterans' organizations;

8 "(h) Religious organizations;

9 "(i) Schools and universities;

"(j) Substance use treatment and recovery facilities, including in patient facilities, outpatient facilities, residential facilities and sober ing centers;

13 **"(k) Public libraries;**

14 "(L) Community health centers;

15 "(m) County public health or behavioral health agencies; and

16 "(n) Special districts.

"(3) To make the bulk purchases of harm reduction supplies under this section, the administrator of the Harm Reduction Clearinghouse Project may use funds from the Opioid Reversal Medication and Harm Reduction Clearinghouse Bulk Purchasing Fund established in section 2 of this 2023 Act or from transfers of funds or donations from the Prescription Drug Purchasing Fund established in ORS 414.318 for the purchase of harm reduction supplies.

24 "(4) The authority may adopt rules to carry out this section.

25 "<u>SECTION 2.</u> (1) The Opioid Reversal Medication and Harm Re-26 duction Clearinghouse Bulk Purchasing Fund is established in the 27 State Treasury, separate and distinct from the General Fund. Interest 28 earned by the Opioid Reversal Medication and Harm Reduction Clear-29 inghouse Bulk Purchasing Fund shall be credited to the fund.

30 "(2) The Opioid Reversal Medication and Harm Reduction Clearing-

1 house Bulk Purchasing Fund consists of:

"(a) Moneys received by the Oregon Health Authority from opioid
 litigation settlements;

4 "(b) Grants awarded for the purpose of addressing substance use
5 and overdose epidemics;

6 "(c) Other gifts, grants, bequests, endowments or donations made
7 to the fund; and

8 "(d) Moneys appropriated to the fund by the Legislative Assembly.

"(3) The moneys in the Opioid Reversal Medication and Harm Reduction Clearinghouse Bulk Purchasing Fund are continuously appropriated to the Oregon Health Authority for the purpose of carrying out
section 1 of this 2023 Act.

13

"SECTION 3. ORS 414.318 is amended to read:

"414.318. The Prescription Drug Purchasing Fund is established separate 14 and distinct from the General Fund. The Prescription Drug Purchasing Fund 15shall consist of moneys appropriated to the fund by the Legislative Assembly 16 and moneys received by the Oregon Health Authority for the purposes es-17 tablished in this section in the form of gifts, grants, bequests, endowments 18 or donations. The moneys in the Prescription Drug Purchasing Fund are 19 continuously appropriated to the authority and shall be used to purchase 20prescription drugs, reimburse pharmacies for prescription drugs and reim-21burse the authority for the costs of administering the Oregon Prescription 22Drug Program, including contracted services costs, computer costs, profes-23sional dispensing fees paid to retail pharmacies and other reasonable pro-24gram costs. Moneys in the fund may be transferred or donated to the 25**Opioid Reversal Medication and Harm Reduction Clearinghouse Bulk** 26Purchasing Fund established under section 2 of this 2023 Act for the 27purpose of purchasing in bulk harm reduction supplies. Interest earned 28on the **Prescription Drug Purchasing** Fund shall be credited to the fund. 29 "SECTION 4. ORS 475.525 is amended to read: 30

"475.525. (1) It is unlawful for any person to sell or deliver, possess with
intent to sell or deliver or manufacture with intent to sell or deliver drug
paraphernalia, knowing that it will be used to unlawfully plant, propagate,
cultivate, grow, harvest, manufacture, compound, convert, produce, process,
prepare, test, analyze, pack, repack, store, contain, conceal, inject, ingest,
inhale or otherwise introduce into the human body a controlled substance
as defined by ORS 475.005.

"(2) For the purposes of this section, 'drug paraphernalia' means all 8 equipment, products and materials of any kind that are marketed for use or 9 designed for use in planting, propagating, cultivating, growing, harvesting, 10 manufacturing, compounding, converting, producing, processing, preparing, 11 testing, analyzing, packaging, repackaging, storing, containing, concealing, 12 injecting, ingesting, inhaling or otherwise introducing into the human body 13 a controlled substance in violation of ORS 475.752 to 475.980. Drug par-14 aphernalia includes, but is not limited to: 15

"(a) Kits marketed for use or designed for use in unlawfully planting,
 propagating, cultivating, growing or harvesting of any species of plant that
 is a controlled substance or from which a controlled substance can be de rived;

"(b) Kits marketed for use or designed for use in manufacturing, compounding, converting, producing, processing or preparing controlled substances;

"(c) Isomerization devices marketed for use or designed for use in in creasing the potency of any species of plant that is a controlled substance;

²⁵ "[(d) Testing equipment marketed for use or designed for use in identifying ²⁶ or in analyzing the strength, effectiveness or purity of controlled substances;]

27 "[(e)] (d) Scales and balances marketed for use or designed for use in
28 weighing or measuring controlled substances;

²⁹ "[(f)] (e) Diluents and adulterants, such as quinine hydrochloride, ³⁰ mannitol, mannite, dextrose and lactose, marketed for use or designed for

HB 2397-2 3/28/23 Proposed Amendments to HB 2397 1 use in cutting controlled substances;

2 "[(g)] (f) Lighting equipment specifically designed for growing controlled
3 substances;

"[(h)] (g) Containers and other objects marketed for use or designed for
use in storing or concealing controlled substances; and

6 "[(*i*)] (**h**) Objects marketed for use or designed specifically for use in 7 ingesting, inhaling or otherwise introducing a controlled substance into the 8 human body, such as:

9 "[(A) Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with or 10 without screens;]

11 "[(*B*) Water pipes;]

12 "[(C) Carburetion tubes and devices;]

13 "[(D)] (A) Smoking and carburation masks;

14 "[(E)] (B) Roach clips, meaning objects used to hold burning material that

15 has become too small or too short to be held in the hand; or

16 "[(F)] (C) Miniature cocaine spoons and cocaine vials[;].

17 "[(G) Chamber pipes;]

18 "[(H) Carburetor pipes;]

19 "[(*I*) Electric pipes;]

- 20 "[(J) Air-driven pipes;]
- 21 "[(K) Chillums;]
- 22 "[(L) Bongs; and]
- 23 "[(M) Ice pipes or chillers.]

"(3) For purposes of this section, 'drug paraphernalia' does not include hypodermic syringes or needles, single-use drug test strips, drug testing tools or any other item designed to prevent or reduce the potential harm associated with the use of opioids and other controlled substances, including but not limited to items that reduce the risk of transmission of infectious disease or prevent injury, infection or overdose. "(4) The provisions of ORS 475.525 to 475.565 do not apply to persons pregistered under the provisions of ORS 475.125 or to persons specified as exempt from registration under the provisions of that statute.

"(5)(a) The provisions of ORS 475.525 to 475.565 do not apply to a person
who sells or delivers marijuana paraphernalia as defined in ORS 475C.373 to
a person 21 years of age or older.

"(b) In determining whether an object is drug paraphernalia under this
section or marijuana paraphernalia under ORS 475C.373, a trier of fact shall
consider, in addition to any other relevant factor, the following:

"(A) Any oral or written instruction provided with the object related to
 the object's use;

"(B) Any descriptive material packaged with the object that explains or
 depicts the object's use;

14 "(C) Any national or local advertising related to the object's use;

¹⁵ "(D) Any proffered expert testimony related to the object's use;

"(E) The manner in which the object is displayed for sale, if applicable;and

18 "(F) Any other proffered evidence substantiating the object's intended use.

"(6) A person acting in good faith is immune from civil liability for
 any act or omission of an action committed during the course of dis tributing an item described in subsection (3) of this section.

"<u>SECTION 5.</u> The amendments to ORS 475.525 by section 4 of this
2023 Act apply to conduct occurring on or after the effective date of
this 2023 Act.".

25

HB 2397-2 3/28/23 Proposed Amendments to HB 2397